DE10258954A1 - Bleeding wound care - Google Patents
Bleeding wound care Download PDFInfo
- Publication number
- DE10258954A1 DE10258954A1 DE2002158954 DE10258954A DE10258954A1 DE 10258954 A1 DE10258954 A1 DE 10258954A1 DE 2002158954 DE2002158954 DE 2002158954 DE 10258954 A DE10258954 A DE 10258954A DE 10258954 A1 DE10258954 A1 DE 10258954A1
- Authority
- DE
- Germany
- Prior art keywords
- composition according
- bleeding
- composition
- wound
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000000740 bleeding effect Effects 0.000 title claims description 19
- 239000000203 mixture Substances 0.000 claims abstract description 31
- 239000002253 acid Substances 0.000 claims abstract description 8
- 230000023555 blood coagulation Effects 0.000 claims abstract description 8
- 239000003054 catalyst Substances 0.000 claims abstract description 8
- 150000007513 acids Chemical class 0.000 claims abstract description 5
- 239000007788 liquid Substances 0.000 claims abstract description 5
- 239000011368 organic material Substances 0.000 claims abstract description 4
- 230000000379 polymerizing effect Effects 0.000 claims abstract description 3
- 239000003085 diluting agent Substances 0.000 claims abstract 2
- 239000003937 drug carrier Substances 0.000 claims abstract 2
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 claims description 11
- 229960002684 aminocaproic acid Drugs 0.000 claims description 11
- 239000011575 calcium Substances 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 4
- QCTBMLYLENLHLA-UHFFFAOYSA-N aminomethylbenzoic acid Chemical compound NCC1=CC=C(C(O)=O)C=C1 QCTBMLYLENLHLA-UHFFFAOYSA-N 0.000 claims description 4
- 229960003375 aminomethylbenzoic acid Drugs 0.000 claims description 4
- 229910052791 calcium Inorganic materials 0.000 claims description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 2
- 102000007327 Protamines Human genes 0.000 claims description 2
- 108010007568 Protamines Proteins 0.000 claims description 2
- GYDJEQRTZSCIOI-UHFFFAOYSA-N Tranexamic acid Chemical compound NCC1CCC(C(O)=O)CC1 GYDJEQRTZSCIOI-UHFFFAOYSA-N 0.000 claims description 2
- 229960002897 heparin Drugs 0.000 claims description 2
- 229920000669 heparin Polymers 0.000 claims description 2
- 230000002163 immunogen Effects 0.000 claims description 2
- 229950008679 protamine sulfate Drugs 0.000 claims description 2
- 229940019333 vitamin k antagonists Drugs 0.000 claims description 2
- 208000032843 Hemorrhage Diseases 0.000 claims 3
- 208000034158 bleeding Diseases 0.000 claims 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims 1
- 229910001628 calcium chloride Inorganic materials 0.000 claims 1
- 239000001110 calcium chloride Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 description 49
- 206010052428 Wound Diseases 0.000 description 42
- 108090000190 Thrombin Proteins 0.000 description 9
- 229960004072 thrombin Drugs 0.000 description 9
- 230000006378 damage Effects 0.000 description 7
- 208000014674 injury Diseases 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 230000004913 activation Effects 0.000 description 4
- 239000006260 foam Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 108010094028 Prothrombin Proteins 0.000 description 3
- 102100027378 Prothrombin Human genes 0.000 description 3
- 239000012876 carrier material Substances 0.000 description 3
- 239000000701 coagulant Substances 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 229940039716 prothrombin Drugs 0.000 description 3
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 2
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical compound C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 108010014173 Factor X Proteins 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 2
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 2
- QQONPFPTGQHPMA-UHFFFAOYSA-N Propene Chemical compound CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 2
- 108010000499 Thromboplastin Proteins 0.000 description 2
- 102000002262 Thromboplastin Human genes 0.000 description 2
- 229920001222 biopolymer Polymers 0.000 description 2
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 230000020764 fibrinolysis Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- AUMYCEAREPLZKC-ODZAUARKSA-N (z)-but-2-enedioic acid;prop-1-ene Chemical compound CC=C.OC(=O)\C=C/C(O)=O AUMYCEAREPLZKC-ODZAUARKSA-N 0.000 description 1
- VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical compound CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102100023804 Coagulation factor VII Human genes 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 108010023321 Factor VII Proteins 0.000 description 1
- 108010080865 Factor XII Proteins 0.000 description 1
- 102000000429 Factor XII Human genes 0.000 description 1
- 108010071289 Factor XIII Proteins 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical group CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 229940019700 blood coagulation factors Drugs 0.000 description 1
- IAQRGUVFOMOMEM-UHFFFAOYSA-N butene Natural products CC=CC IAQRGUVFOMOMEM-UHFFFAOYSA-N 0.000 description 1
- 235000010410 calcium alginate Nutrition 0.000 description 1
- 239000000648 calcium alginate Substances 0.000 description 1
- 229960002681 calcium alginate Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 229940012413 factor vii Drugs 0.000 description 1
- 229940012444 factor xiii Drugs 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000005541 medical transmission Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 108010034963 tachocomb Proteins 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0076—Sprayable compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/008—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/009—Materials resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/21—Acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/418—Agents promoting blood coagulation, blood-clotting agents, embolising agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Materials Engineering (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Die Erfindung betrifft eine Zusammensetzung zur Wundversorgung in Form einer Flüssigkeit und/oder eines Gels, enthaltend einen synthetischen Katalysator, welcher die Blutgerinnung fördert und welcher ausgewählt ist aus der Gruppe der pharmazeutisch annehmbaren Säuren und/oder Lysinanaloga, ein an Luft aushärtendes und/oder polymerisierendes organisches Material sowie wenigstens einen pharmazeutisch annehmbaren Träger oder Verdünner.The invention relates to a composition for wound care in the form of a liquid and / or a gel, containing a synthetic catalyst which promotes blood clotting and which is selected from the group of pharmaceutically acceptable acids and / or lysine analogs, an air-curing and / or polymerizing organic material and at least one pharmaceutically acceptable carrier or diluent.
Description
Die Erfindung betrifft eine pharmazeutische Zusammensetzung, welche als therapeutisch aktiven Wirkstoff ein Lysinanalogon, vorzugsweise Epsilon-Aminocapronsäure (EACA) enthält und die zur Behandlung von Nachblutungen oder Sickerblutungen an großflächigen, tiefen und/oder tiefliegenden Wunden geeignet ist.The invention relates to a pharmaceutical composition, which is a therapeutically active ingredient, preferably a lysine analog Epsilon-aminocaproic acid (EACA) contains and to treat post-bleeding or seeping bleeding large-scale, deep and / or deep-lying wounds is suitable.
Im physiologisch gesunden Organismus hat das ausgewogene System der Blutgerinnung die Aufgabe kleinere und größere Verletzungen von Endothelien oder ganzen Gewebestrukturen abzudichten und somit einen größeren, möglicherweise lebensbedrohlichen Blutverlust zu vermeiden.In the physiologically healthy organism the balanced system of blood coagulation has the smaller task and major injuries to seal off endothelia or entire tissue structures and thus a bigger one, possibly to avoid life-threatening blood loss.
Der zentrale Vorgang für die Blutgerinnung ist die proteolytische Aktivierung von Prothrombin zu Thrombin.The central process for blood clotting is the proteolytic activation of prothrombin to thrombin.
Bei Gewebeverletzungen wird die Aktivierung des sogenannten „exogenen Systems" durch ein Lipoprotein, Thromboplastin (III), das bei der Zerstörung von Gewebezellen aus dem endoplasmatischen Reticulum freigesetzt wird, induziert. Thromboplastin aktiviert dabei den Plasmafaktor VII, der mit Phospholipiden und Ca2+ einen Komplex bildet. Dieser Komplex ist maßgeblich für die Aktivierung des Faktors X zu Xa verantwortlich, einer Protease, welche schließlich Prothrombin in Thrombin umwandelt.In the case of tissue injuries, the activation of the so-called "exogenous system" is induced by a lipoprotein, thromboplastin (III), which is released from the endoplasmic reticulum when tissue cells are destroyed. Thromboplastin activates plasma factor VII, which combines with phospholipids and Ca 2+ This complex is largely responsible for the activation of factor X to form Xa, a protease that ultimately converts prothrombin to thrombin.
Bei kleineren Endotheldefekten erfolgt die Aktivierung des Faktors X über eine Kaskade von Plasmafaktoren. Sobald der im Plasma gelöste Faktor XII mit anderen Oberflächen als dem Endothel der Gefäße in Berührung kommt, wird er aktiviert (XIIa) und startet damit das sogenannte „endogene System". Am endogenen System sind im Weiteren die Plasmafaktoren XI, XIa, IX, IXa, VIII, Ca2+ sowie ein Thrombozytenfaktor (TF3) beteiligt, die schließlich die proteolytische Umwandlung von Prothrombin zu Thrombin durch den aktivierten Faktor Xa induzieren.In the case of smaller endothelial defects, factor X is activated via a cascade of plasma factors. As soon as the factor XII dissolved in the plasma comes into contact with surfaces other than the endothelium of the vessels, it is activated (XIIa) and thus starts the so-called “endogenous system”. The plasma factors XI, XIa, IX, IXa are also on the endogenous system , VIII, Ca 2+ and a platelet factor (TF3), which ultimately induce the proteolytic conversion of prothrombin to thrombin by the activated factor Xa.
Thrombin wirkt dann auf Fibrinogen ein, welches dadurch zunächst in monomeres lösliches Fibrin umgewandelt wird und nachfolgend unter dem Einfluss von Faktor XIII und Ca2+ zu stabilen Fibringerinnseln polymerisiert und dabei Verletzungen abdichtet.Thrombin then acts on fibrinogen, which is thereby first converted into monomeric soluble fibrin and subsequently polymerized to stable fibrin clots under the influence of factor XIII and Ca 2+ , thereby sealing off injuries.
Der gesamte Vorgang der Blutgerinnung dauert im ungestörten System 3 bis 5 Minuten und damit zu lange, um bei großflächigen oder stark blutenden Wunden tatsächlich einen erhöhten Blutverlust zu vermeiden.The entire process of blood clotting lasts in the undisturbed System 3 to 5 minutes and therefore too long to work with large areas or heavily bleeding wounds actually an elevated To avoid blood loss.
Zur Versorgung von blutenden Wunden werden daher verschiedenen Methoden und Substanzen eingesetzt.For the care of bleeding wounds therefore different methods and substances are used.
In der einfachsten Form werden sterile Tücher, Kompressen oder ähnliche Materialien in Form von Verbänden auf eine Wunde aufgebracht. Durch die Saugfähigkeit des Verbandmaterials wird dabei die Blutungsgeschwindigkeit im Wundbereich verringert, sodass die natürlich einsetzende Blutgerinnung ausreicht, um eine Wunde zu verschließen.In the simplest form, they become sterile towels, Compresses or the like Materials in the form of bandages applied to a wound. Due to the absorbency of the dressing material the rate of bleeding in the wound area is reduced, so of course the onset of blood coagulation is sufficient to close a wound.
Bei stark blutenden Wunden kommen Wundabdeckungen, wie z.B. die TachoComb® Wundabdeckung (Hafslund Nycomed Pharma), die aus einer Kollagenmatrix, welche mit gerinnungsfördernden Substanzen einseitig oder allseitig beschichtet ist, besteht, zum Einsatz. Als hochwirksame gerinnungsfördernde Substanzen werden z.B. das aus Rinderblut gewonnene Thrombin und das aus menschlichen Blut gewonnene Fibrinogen eingesetzt.In the case of heavily bleeding wounds, wound covers are used, such as the TachoComb ® wound cover (Hafslund Nycomed Pharma), which consists of a collagen matrix which is coated on one side or on all sides with coagulation-promoting substances. For example, thrombin obtained from bovine blood and fibrinogen obtained from human blood are used as highly effective coagulation-promoting substances.
Da jedoch die Verwendung von menschlichen Bestandteilen wegen einer erhöhten Gefahr der Krankheitsübertragung als gravierender Nachteil betrachtet wird, gab es Bestrebungen fibrinogen-freie Wundabdeckungen herzustellen.However, since the use of human Ingredients because of an increased Risk of disease transmission Fibrinogen-free wound coverings have been sought as a serious disadvantage manufacture.
Aus
Nach wie vor ist bei solchen Wundabdeckungen die Verwendung von tierischen Bestandteilen, z.B. Thrombin, problematisch. Zum einen besteht das erhebliche Risiko der Übertragung von für den Menschen gefährlichen Krankheiten wie z.B. BSE (Bovine Spongiforme Encephalitis), zum anderen ist die Gewinnung von Blutgerinnungsfaktoren aus tierischem Material aufwendig und teuer. Ein weiterer Nachteil ist, dass Wundabdeckungen, die tierisches Thrombin enthalten, besonders gelagert werden müssen, um ein vorzeitiges Verderben zu verhindern.There is still such wound coverings the use of animal ingredients, e.g. Thrombin, problematic. First, there is a significant risk of transmission for humans dangerous Diseases such as BSE (Bovine Spongiform Encephalitis), to another is the extraction of blood coagulation factors from animal Material complex and expensive. Another disadvantage is that wound coverings, which contain animal thrombin must be stored in order to to prevent premature spoilage.
Ein entscheidender Nachteil der bekannten Wundabdeckungen ist auch ihre mangelhafte Anpassung an die individuellen Oberflächenstrukturen bzw. Ausdehnungen einer Wunde. Insbesondere großflächige oder tiefe, nässende oder nachblutende Wunden können nicht optimal mit den bekannten, in ihrer Struktur festgelegten Wundabdeckungen versorgt werden.A crucial disadvantage of the known wound coverings is also their inadequate adaptation to the individual surface structures or extent of a wound. Especially large or deep, oozing or bleeding wounds not optimal with the known, in their structure Wound covers are supplied.
Es ist daher Aufgabe der Erfindung, eine pharmazeutische Zusammensetzung zur Wundversorgung bereitzustellen, die keine menschlichen oder tierischen Bestandteile enthält und eine individuelle Versorgung und Abdeckung großflächiger, tiefer oder tiefliegender Wunden bei gleichzeitiger Hemmung von Sicker- oder Nachblutungen ermöglicht.It is therefore an object of the invention to provide a pharmaceutical composition for wound care, which does not contain any human or animal components and a individual coverage and coverage of large areas, deeper or lower Wounds with simultaneous inhibition of seepage or post-bleeding allows.
Diese Aufgabe wird durch das Bereitstellen einer flüssigen, gelartigen oder gelatinösen pharmazeutischen Zusammensetzung erreicht, welche die Blutgerinnung mittels synthetischer Katalysatoren, insbesondere pharmazeutisch annehmbarer Säuren, beschleunigt und welche sich flächig über die Wunde und/oder in die Wunde sprühen oder schäumen lässt.This task is accomplished by providing a liquid, gelatinous or gelatinous pharmaceutical composition that achieves blood clotting by means of synthetic catalysts, in particular pharmaceutical acceptable acids, accelerated and which are flat over the Spray wound and / or into the wound or foam leaves.
Die Konsistenz der Zusammensetzung wird dabei durch die Verwendung eines an Luft aushärtenden und/oder polymerisierenden organischen Trägermaterials oder Biopolymers bestimmt .The consistency of the composition will determined by the use of an air-curing and / or polymerizing organic carrier material or biopolymer.
Geeignete Trägermaterialien zur Herstellung sind dabei Gelatine- oder Collagenverbindungen, Zellulose-Sulfat, Calzium- und/oder Calzium/Sodium-Alginat, Kautschuk sowie auf Äthylen, Propen, Buten, Isobutylen, Butadien, Isopren, Maleinsäure, Propylenhydrogenmaleat und/oder Methylacrylat basierende Polymeren. Es ist dem Fachmann bekannt, wie diese Materialien zu verarbeiten sind, um die gewünschte Konsistenz einzustellen und so die erfindungsmäßige Zusammensetzung herzustellen. Ebenso ist dem Fachmann bekannt, welche Gase oder Schäummittel in geeigneten Dispensern oder Zerstäubern zuzusetzen sind, um die erfindungsmäßige Zusammensetzung situationsgerecht applizieren zu können.Suitable carrier materials for the production are thereby gelatin or collagen compounds, cellulose sulfate, calcium and / or calcium / sodium alginate, rubber and on ethylene, Propene, butene, isobutylene, butadiene, isoprene, maleic acid, propylene hydrogen maleate and / or methyl acrylate based polymers. It is the specialist Known how to process these materials to the desired consistency adjust and thus produce the composition according to the invention. As well the person skilled in the art knows which gases or foaming agents in suitable dispensers or atomizers are to be added in order for the composition according to the invention to suit the situation to be able to apply.
Durch die zunächst flüssige oder zumindest formbare Konsistenz der Zusammensetzung wird gewährleistet, dass die gerinnungsfördernden Katalysatoren nicht nur außen auf die Wunde aufgelegt werden, sondern auch an allen Stellen innerhalb der Wunde eine optimale Bereitstellung der gerinnungsfördernden Faktoren und damit Katalyse der Blutgerinnung möglich wird.Due to the initially liquid or at least malleable Consistency of the composition ensures that the coagulant Catalysts not just outside be applied to the wound, but also in all places within the wound optimally provides the coagulant Factors and thus catalysis of blood clotting is possible.
Darüber hinaus erlaubt das Aufsprühen und/oder Aufschäumen der erfindungsgemäßen Zusammensetzung in der Wunde bzw. auf die Wunde eine deutlich verbesserte und damit individuell besser angepasste Wundversorgung.It also allows spraying and / or foam the composition of the invention in the wound or on the wound a significantly improved and thus individually better adapted wound care.
Bei leichteren Blutungen oder nässenden Wunden wird hierbei eine dünne Schicht der erfindungsgemäßen Zusammensetzung auf die Wunde aufgesprüht werden. Falls die Verletzung in Teilbereichen stärker blutet, können solche Teilbereiche intensiver besprüht werden, sodass eine dickere und damit länger haltbare Schicht der erfindungsgemäßen Zusammen-setzung die Wunde abdeckt.With minor bleeding or oozing wounds becomes a thin one Layer of the composition according to the invention sprayed on the wound become. If the injury bleeds more heavily in some areas, it can Partial sprayed areas so that a thicker and therefore longer-lasting layer of the composition according to the invention covers the wound.
Für intensive Blutungen oder tiefe Verletzungen wird die erfindungsgemäße Zusammensetzung in Form einer dicken und aufgrund der schwammartigen Oberflächenstruktur auch saugfähigen Schaumhülle in die Wunde gelegt. Das Blut versickert so zunächst in der schwammartigen Schaumhülle, wobei es überall mit dem gerinnungsfördernden Katalysator in Berührung kommt. Durch das Versickern wird zum einen eine größere Oberfläche für die Katalyse bereitgestellt, gleichzeitig aber auch ein Wegschwemmen der erfindungsgemäßen Zusammensetzung verhindert.For intensive bleeding or deep injuries, the composition according to the invention is in Form of a thick and due to the spongy surface structure also absorbent foam case placed in the wound. The blood then seeps into the sponge-like Foam case, being everywhere with the coagulant Catalyst in contact comes. The infiltration creates a larger surface for catalysis provided, but at the same time also prevents the composition according to the invention from washing away.
Für den Einsatz bei im Innenbereichen liegenden Wunden oder Organverletzungen ist das Trägermaterial oder Biopolymer vorzugsweise nicht immunogen, jedoch absorbierbar und biologisch abbaubar, sodass es nachdem die Blutung gestillt ist, nicht entfernt werden muss, sondern langsam zersetzt wird.For use for internal wounds or organ injuries is the carrier material or biopolymer, preferably not immunogenic, but absorbable and biodegradable so that it stops the bleeding after is, does not have to be removed, but is slowly decomposed.
Für die Behandlung von äußeren Verletzungen kommt vorzugsweise eine Kombination aus absorbierbarem, biologisch abbaubarem, aber auch nicht-abbaubarem synthetischen, organischen Materialen oder Polymeren zum Einsatz. Bei einer solchen Kombination lösen sich, nachdem die Blutung gestillt ist, die wundnahen Bereiche vermehrt auf, wodurch die übrigen Bestandteile der Zusammensetzung leicht zu entfernen sind.For the treatment of external injuries preferably comes a combination of absorbable, biological degradable, but also non-degradable synthetic, organic Materials or polymers. With such a combination dissolve, after the bleeding has stopped, the areas near the wound are increased on, causing the rest Components of the composition are easy to remove.
Optional können Verletzungen, die mit der erfindungsgemäßen Zusammensetzung behandelt wurden, sobald der Schutzfilm beginnt sich zu festigen und/oder auszuhärten, mit herkömlichen Verbandsmaterialien eingebunden werden.Optionally, injuries associated with the composition of the invention treated as soon as the protective film begins to set and / or harden, with traditional Bandage materials are integrated.
Die erfindungsgemäße Zusammensetzung enthält einen gerinnungsfördernden, synthetischen Katalysator, insbesondere eine pharmazeutisch annehmbare Säure, welche den pH-Wert im Wundbereich um 0.1 bis 3 heraufsetzt. Vorzugsweise werden hierfür Säuren oder Lysinanaloga z.B. die auch hochwirksame Hemmstoffe der Fibrinolyse sind, nämlich Epsilon-Aminocapronsäure (EACA), p-Aminomethylbenzoesäure (PAMBA) oder Tranexamsäure (AMCHA) oder analoge Substanzen, eingesetzt.The composition according to the invention contains a clotting, synthetic catalyst, especially a pharmaceutically acceptable one Acid, which increases the pH in the wound area by 0.1 to 3. Preferably be for this acids or lysine analogs e.g. which are also highly effective inhibitors of fibrinolysis are namely epsilon aminocaproic acid (EACA), p-aminomethylbenzoic acid (PAMBA) or tranexamic acid (AMCHA) or analogous substances.
Im Rahmen der Erfindung durchgeführte Untersuchungen haben ergeben, dass selbst stärker blutende Wunden erfolgreich mit der erfindungsgemäßen Zusammensetzung versorgt und abgedeckt werden können, da die Zugabe von pharmazeutisch annehmbaren Säuren, insbesondere von EACA, ein Wegschwemmen der aufgesprühten Zusammensetzung beträchtlich vermindert.Investigations carried out within the scope of the invention have shown that even heavier bleeding Wounds successfully supplied with the composition according to the invention and can be covered since the addition of pharmaceutically acceptable acids, especially EACA, a wash away of the sprayed on Composition considerable reduced.
Gemäß weiterer Ausführungsformen kann die erfindungsgemäße Zusammensetzung als weitere gerinnungsfördernde und damit vorteilhafte Komponenten Calziumdonatoren, insbesondere CaCl2 und/oder Substanzen, welche die Wirkung von Heparin oder Vitamin-K-Antagonisten neutralisieren, insbesondere Protaminsulfat, enthalten.According to further embodiments, the composition according to the invention can contain calcium donors, in particular CaCl 2 and / or substances which neutralize the action of heparin or vitamin K antagonists, in particular protamine sulfate, as further coagulation-promoting and thus advantageous components.
Eine bevorzugte Verwendung der erfindungsgemäßen Zusammensetzung ist in der Erstversorgung von Wunden bei Mensch und Tier nach Unfällen oder Operationen. Hier besonders zur Abdeckung und Ausgleich von Organdefekten, bei welchen dies mit körpereigenem Gewebematerial nicht möglich ist und besonders das Risiko der Nachblutung besteht.A preferred use of the composition according to the invention is in the primary care of wounds in humans and animals after accidents or Operations. Here especially to cover and compensate for organ defects, in which this with the body's own Fabric material not possible and there is a particular risk of subsequent bleeding.
Ein einfaches Aufsprühen oder Einschäumen der Wunde mit der erfindungsgemäßen Zusammensetzung stoppt oder verringert wenigstens dabei einen schleichenden Blutverlust oder Blutungen an großflächigen oder tiefen Wunden.A simple spray or lather the wound with the composition according to the invention stops or at least reduces creeping blood loss or bleeding on large areas or deep wounds.
Eine weitere bevorzugte Verwendung der erfindungsgemäßen Zusammensetzung ist bei und während Operationen gegeben, um ein Einbluten des Operationsortes aus verletzen Geweben durch Einsprühen oder Einschäumen zu verringern.Another preferred use the composition of the invention is during and during Operations given to injure bleeding from the surgical site Weave by spraying or lathering to reduce.
Schließlich wird die erfindungsgemäße Zusammensetzung auch bevorzugt in der Nachversorgung von großflächigen, schlecht heilenden, nässenden, nachblutenden Wunden bei Mensch und Tier eingesetzt.Finally, the composition of the invention also preferred in the aftercare of large, poorly healing, weeping, bleeding wounds used in humans and animals.
Ohne dass Verbände nötig sind, kann mit der erfindungsgemäßen Zusammensetzung eine sichere, sterile und blutungsstillende Wundversorgung sowohl in der Erstversorgung, während Operationen als auch in der Nachversorgung bereitgestellt werden.Without the need for bandages, the composition according to the invention can be used safe, sterile and hemostatic wound care both in primary care while Operations as well as aftercare are provided.
Claims (10)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2002158954 DE10258954A1 (en) | 2002-12-16 | 2002-12-16 | Bleeding wound care |
| EP03789254A EP1581269A1 (en) | 2002-12-16 | 2003-12-12 | Haemostatic wound dressing |
| PCT/EP2003/014163 WO2004054632A1 (en) | 2002-12-16 | 2003-12-12 | Haemostatic wound dressing |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2002158954 DE10258954A1 (en) | 2002-12-16 | 2002-12-16 | Bleeding wound care |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE10258954A1 true DE10258954A1 (en) | 2004-07-08 |
Family
ID=32477710
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2002158954 Withdrawn DE10258954A1 (en) | 2002-12-16 | 2002-12-16 | Bleeding wound care |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP1581269A1 (en) |
| DE (1) | DE10258954A1 (en) |
| WO (1) | WO2004054632A1 (en) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7846141B2 (en) | 2002-09-03 | 2010-12-07 | Bluesky Medical Group Incorporated | Reduced pressure treatment system |
| GB0224986D0 (en) | 2002-10-28 | 2002-12-04 | Smith & Nephew | Apparatus |
| US8062272B2 (en) | 2004-05-21 | 2011-11-22 | Bluesky Medical Group Incorporated | Flexible reduced pressure treatment appliance |
| US10058642B2 (en) | 2004-04-05 | 2018-08-28 | Bluesky Medical Group Incorporated | Reduced pressure treatment system |
| US7909805B2 (en) | 2004-04-05 | 2011-03-22 | Bluesky Medical Group Incorporated | Flexible reduced pressure treatment appliance |
| GB0722820D0 (en) | 2007-11-21 | 2008-01-02 | Smith & Nephew | Vacuum assisted wound dressing |
| ES2555204T3 (en) | 2007-11-21 | 2015-12-29 | T.J. Smith & Nephew Limited | Suction and bandage device |
| HUE043133T2 (en) | 2007-11-21 | 2019-07-29 | Smith & Nephew | wound dressing |
| US11253399B2 (en) | 2007-12-06 | 2022-02-22 | Smith & Nephew Plc | Wound filling apparatuses and methods |
| GB0723875D0 (en) | 2007-12-06 | 2008-01-16 | Smith & Nephew | Wound management |
| US20130096518A1 (en) | 2007-12-06 | 2013-04-18 | Smith & Nephew Plc | Wound filling apparatuses and methods |
| GB0803564D0 (en) | 2008-02-27 | 2008-04-02 | Smith & Nephew | Fluid collection |
| GB0902816D0 (en) | 2009-02-19 | 2009-04-08 | Smith & Nephew | Fluid communication path |
| US9061095B2 (en) | 2010-04-27 | 2015-06-23 | Smith & Nephew Plc | Wound dressing and method of use |
| GB201011173D0 (en) | 2010-07-02 | 2010-08-18 | Smith & Nephew | Provision of wound filler |
| GB201020005D0 (en) | 2010-11-25 | 2011-01-12 | Smith & Nephew | Composition 1-1 |
| CN107033596A (en) | 2010-11-25 | 2017-08-11 | 史密夫及内修公开有限公司 | Composition I-II and products thereof and purposes |
| US20150159066A1 (en) | 2011-11-25 | 2015-06-11 | Smith & Nephew Plc | Composition, apparatus, kit and method and uses thereof |
| EP2968647B1 (en) | 2013-03-15 | 2022-06-29 | Smith & Nephew plc | Wound dressing sealant and use thereof |
| US20160120706A1 (en) | 2013-03-15 | 2016-05-05 | Smith & Nephew Plc | Wound dressing sealant and use thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2339805A1 (en) * | 1976-01-28 | 1977-08-26 | Torossian Fernand | Fluid loss esp. bleeding prevention - by spraying an absorbent material which swells on contact with the fluid |
| DE3133896A1 (en) * | 1981-08-27 | 1983-03-24 | Togal-Werk AG, 8000 München | Use of 2-aminoheptane |
| US4637815A (en) * | 1985-08-06 | 1987-01-20 | Lemole Gerald M | Irrigational hemostatic solution |
| EP0365704A1 (en) * | 1988-10-26 | 1990-05-02 | Zentralna Problemna Laboratoria Po Kryobiologia I Lyophilisazia | Biopreparation for the hemostasis in stomach bleedings |
| DD292840A5 (en) * | 1990-03-15 | 1991-08-14 | Veb Lederwerk "August Apfelbaum",De | METHOD FOR PRODUCING WOUND-ADHESIVE HAEMOSTYPTICS |
| ATE204742T1 (en) * | 1993-04-30 | 2001-09-15 | Eastern Virginia Med School | TOPICALLY APPLICABLE PREPARATION FOR REEPITHELIZATION IN PERSISTENT EPITHELIUM DEFECTS |
| ES2227542T3 (en) * | 1993-11-03 | 2005-04-01 | Clarion Pharmaceuticals, Inc. | HEMOSTATIC PATCH. |
| EP0803255A4 (en) * | 1994-06-03 | 1999-06-30 | Tsumura & Co | Medicinal composition |
| JPH09124878A (en) * | 1995-10-31 | 1997-05-13 | Shiseido Co Ltd | Gel composition |
| JP3447177B2 (en) * | 1996-05-17 | 2003-09-16 | 株式会社資生堂 | Gel composition |
| AU1773600A (en) * | 1998-12-21 | 2000-07-12 | Aps Kbus 8 Nr. 4788 | Topical treatment of skin disease |
| US20030072805A1 (en) * | 2000-01-11 | 2003-04-17 | Kazuyuki Miyazawa | Microgel and external compositions containing the same |
| EP1190724B8 (en) * | 2000-09-22 | 2006-05-03 | Perlei Medical Produkte GmbH | Use of antifibrinolytic agents for preparing sponges, compresses or dressings |
-
2002
- 2002-12-16 DE DE2002158954 patent/DE10258954A1/en not_active Withdrawn
-
2003
- 2003-12-12 EP EP03789254A patent/EP1581269A1/en not_active Ceased
- 2003-12-12 WO PCT/EP2003/014163 patent/WO2004054632A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP1581269A1 (en) | 2005-10-05 |
| WO2004054632A1 (en) | 2004-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE10258954A1 (en) | Bleeding wound care | |
| DE69433939T2 (en) | HEMOSTATIC PLASTER | |
| DE69629010T2 (en) | SELF-SUPPORTING AREA MADE OF CROSS-LINKED FIBRINE FOR INHIBITING POST-OPERATIVE ADHESIONS | |
| DE69425509T2 (en) | LOCAL ADMINISTRATION OF FIBRINOLYSIS REINFORCING AGENTS | |
| EP2981301B1 (en) | Medical dressing | |
| USRE39321E1 (en) | Supplemented and unsupplemented tissue sealants, methods of their production and use | |
| US9408913B2 (en) | Composition and dressing for wound treatment | |
| CA2513319C (en) | Hemostatic material comprising thrombin, fibrinogen and bioabsorbable synthetic nonwoven fabric | |
| WO2021015631A9 (en) | Multilayer nanofibres with bioactive compositions for wound healing management | |
| Baxter | Management of burn wounds | |
| CA2224253A1 (en) | Chitin hydrogels, methods of their production and use | |
| WO1996040033A1 (en) | Non-biological patch for hemostasis | |
| CA2673712A1 (en) | Medicaments and methods comprising a compound that promotes oestrogenic activity for wound healing | |
| EP2018835B1 (en) | Agent-eluting plaster | |
| Valachova et al. | Skin wound healing with composite biomembranes loaded by tiopronin or captopril | |
| JP3550685B2 (en) | Wound healing agent | |
| EP1190724B1 (en) | Use of antifibrinolytic agents for preparing sponges, compresses or dressings | |
| JP2010527673A (en) | Novel active ingredients and their use in fusion | |
| AT407484B (en) | MEDICINES FOR PROMOTING Wound Healing | |
| EP1183043A2 (en) | Medicament for localised application, containing fibrinogen, thrombin, transglutaminases and proteinase inhibitors | |
| Santhanam et al. | Bovine based collagen dressings in wound care management | |
| DE60021350T2 (en) | MMP-HEMMER AT BINDING WEB SUBSTANCE | |
| CN1285339C (en) | Adhesive bandage containing hyaluronic acid biological composition | |
| RU2526183C1 (en) | Haemostatic anti-burn wound-healing composition | |
| Osada et al. | Coverage of free flap vascular pedicles by basic fibroblast growth factor-impregnated collagen-gelatin sponge without skin graft |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8127 | New person/name/address of the applicant |
Owner name: HEMATRIS WOUND CARE GMBH, 85521 OTTOBRUNN, DE |
|
| 8110 | Request for examination paragraph 44 | ||
| R016 | Response to examination communication | ||
| R119 | Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee |